Your browser doesn't support javascript.
loading
Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.
Schwarz, T; Spaczynski, M; Kaufmann, A; Wysocki, J; Galaj, A; Schulze, K; Suryakiran, P; Thomas, F; Descamps, D.
Afiliação
  • Schwarz T; Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Würzburg, Germany.
BJOG ; 122(1): 107-18, 2015 Jan.
Article em En | MEDLINE | ID: mdl-25208608
ABSTRACT

OBJECTIVE:

Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women.

DESIGN:

Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase-III study (NCT00196937).

SETTING:

Six centres in Germany and Poland. POPULATION 488 healthy women (aged 15-55 years, age-stratified into groups 15-25, 26-45, and 46-55 years) who received three vaccine doses in the primary study.

METHODS:

Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOME

MEASURES:

Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1.

RESULTS:

At 6 years after dose 1, all women were seropositive for anti-HPV-16 and ≥97% were seropositive for anti-HPV-18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV-16 and anti-HPV-18, respectively. In all age groups, GMTs were higher (anti-HPV-16, 9.3-45.1-fold; anti-HPV-18, 4.3-19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81-0.96 (anti-HPV-16) and 0.69-0.84 (anti-HPV-18). Exploratory modelling based on the 6-year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV-18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported.

CONCLUSIONS:

At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Infecções por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Vacinas contra Papillomavirus / Anticorpos Antivirais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Revista: BJOG Assunto da revista: GINECOLOGIA / OBSTETRICIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Infecções por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Vacinas contra Papillomavirus / Anticorpos Antivirais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Revista: BJOG Assunto da revista: GINECOLOGIA / OBSTETRICIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha